Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab in ES-SCLC
NCT04702880Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Primary completion
- May 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of Atigotatug in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Started Mar 2021; status: completed.
02
Drugs
Atigotatug
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04702880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702880.